contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


alligator-bioscience-announces-resignation-of-malin-carlsson-as-chief-operating-officer

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Alligator Bioscience is a research-based biotechnology company that uses patented technology to develop biological drug candidates in inflammation and cancer. The company is active in the former part of the drug development chain. Alligator Bioscience has a global technology platform and is active in a rapidly growing segment of the pharmaceutical market - protein drugs. The company was founded in 2001 and is headquartered in Lund, Sweden.

Alligator Bioscience

Lund, Sweden, August 17, 2023 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the resignation of Malin Carlsson as the company's Chief Operating Officer (COO). Dr Carlsson will...

<div class="mfn-body">Lund, Sweden, August 17, 2023 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the resignation of Malin Carlsson as the company's Chief Operating Officer (COO). Dr Carlsson will leave her role at the end of October to assume an executive role in a global pharma company. Dr Carlsson’s responsibilities will be transferred to other members of the Management team.<blockquote>"We would like to thank Malin for the dedication she has shown during her time at Alligator and in particular her valuable contribution to our mitazalimab program, which is continuing to make excellent clinical progress," said Søren Bregenholt, CEO of Alligator Bioscience. "Malin's experience in immunology and drug development, and the new role she is about to embark upon, demonstrate how Alligator is able to attract talents in the biotech industry, and we wish her the very best for the future."</blockquote> <a rel="noopener" href="https://alligatorbioscience.se/en/news/alligator-bioscience-announces-positive-second-interim-efficacy-analysis-from-mitazalimab-optimize-1-phase-2-study-in-1st-line-pancreatic-cancer/">Alligator recently announced positive second interim results from the ongoing OPTIMIZE-1 Phase 2 study</a> evaluating the company's lead asset mitazalimab in combination with chemotherapy, mFOLFIRINOX, in 1st line metastatic pancreatic cancer. The study continues to progress well and remains on track for top-line readout in early Q1 2024.</div><div class="mfn-footer mfn-contacts mfn-127b8acc461b">For further information, please contact:<hr>Søren Bregenholt, CEO E-mail:&nbsp;<a rel="noopener" href="mailto:sbr@alligatorbioscience.com?subject=Alligator%20Bioscience%20to%20Present%20Additional%20data%20of%20ATOR-1017%20First-in-Human%20Study%20via%20poster%20presentation%20at%20ASCO%20Annual%20Meeting%202022">soren.bregenholt@alligatorbioscience.com</a> Phone: +46 (0) 46 540 82 00LifeSci Advisors Investor Relations Guillaume van Renterghem E-mail:&nbsp;<a rel="noopener" href="mailto:gvanrenterghem@lifesciadvisors.com?subject=Alligator%20Bioscience%20to%20Present%20Additional%20data%20of%20ATOR-1017%20First-in-Human%20Study%20via%20poster%20presentation%20at%20ASCO%20Annual%20Meeting%202022">gvanrenterghem@lifesciadvisors.com</a> Phone: +41 (0) 76 735 01 31</div><div class="mfn-footer mfn-about mfn-76021e509ec4">About Alligator Bioscience<hr>Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.For more information, please visit <a rel="noopener" href="https://www.alligatorbioscience.se/en">alligatorbioscience.com</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/7da52003-3f6d-498d-b48b-804bbf1dd7b6/alligator-bioscience-announces-resignation-of-malin-carlsson-as-chief-operating-officer.pdf" class="mfn-generated mfn-primary">Alligator Bioscience announces resignation of Malin Carlsson as Chief Operating Officer</a></div>

Alligator Bioscience announces resignation of Malin Carlsson as Chief Operating Officer